| Ticker: | ABEO |
| Current Price: | $2.42 |
| % Daily Change: | 5.68% |
| Volume (1,000s): | 3,174.27 |
| Average Volume (1,000s): | 1,237.39 |
| Market Cap (M): | $138.30 |
| 1/2/2024 Price: | $5.61 |
| Change Since Inception: | -56.86% |
1330 Avenue of the Americas
33rd Floor
New York, NY 10019
Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona’s clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa in Phase 3 development, as well as ABO-102 and ABO-101, novel AAV-based gene therapies for Sanfilippo syndrome types A and B (MPS IIIA and MPS IIIB), respectively, in Phase 1/2 development. The Company’s portfolio of AAV-based gene therapies also features ABO-201 for CLN3 disease. Abeona’s novel, next-generation AIM™ capsids have shown potential to improve tropism profiles for a variety of devastating diseases. Abeona’s fully functional, gene and cell therapy GMP manufacturing facility produces EB-101 for the pivotal Phase 3 VIITAL™ study and is capable of clinical and commercial production of AAV-based gene therapies.